Ruti Aga's Six-Year Ban: A Forged Prescription, a Misclassified Drug, and the Arithmetic of Two Plus Four

The clinic printed on the prescription does not appear in any register. The person who signed it holds no medical registration — he is a member of the athlete's family. And when asked where the pad came from, the answer was: an old pad left over from a former workplace. That clinic denies the claim in plain terms.

Ethiopian marathon runner Ruti Aga has been banned for six years by the Athletics Integrity Unit. Two years because a sample taken after she won a half marathon in China in March returned methylprednisolone. Four years because the paperwork she produced during the investigation was fabricated.

Two and four, six. That is the arithmetic the entire case rests on, and it is the arithmetic no headline touched. Everything else — the 2026 Tokyo Marathon title, three World Marathon Majors podiums, the 2:18 range — now sits underneath that one line.

I have spent a decade reading AIU statements and reasoned decisions as PDFs. One pattern repeats: paperwork does more damage than pharmacology. Aga's case is the cleanest illustration of a rule the sport still has not learned.

Context: what the statement contains, and what it does not

The AIU statement is a short list of facts. A half marathon in China in March. Aga won it. An in-competition sample came back positive for methylprednisolone. She cited a knee injury and produced a prescription. The prescription was found to be forged. Outcome: two years for the presence violation, four years for tampering. Six years in total, effective 10 September, the same date from which she had been provisionally suspended. The statement was issued on a Thursday.

Now the list of what is absent. No name for the Chinese half marathon. No mark. No date. No year for the March race. No scope for the disqualification — whether the race result was annulled, whether prize money was clawed back, whether ranking points after that date were forfeited. No statement from the Ethiopian federation. Not a word on the role of the agent or management.

That inventory matters because it tells us what we hold. We hold a press release, not a reasoned decision. The difference is decisive here.

Aga is 32. She won Tokyo in 2026. She has three second-place finishes at World Marathon Majors. Her personal best — from memory, and I print this as recall rather than verified record — was around 2:18:34 in Berlin 2026, where she finished second, and around 2:20:40 in Tokyo 2026, where she won. None of these figures appear in the source.

Core: S9, and the error every headline repeated

Most English-language reports described methylprednisolone as a prohibited steroid and said WADA classifies it as performance-enhancing. That sentence is technically wrong, and the error dismantles any proper reading of the case.

Methylprednisolone is a glucocorticoid. On the WADA Prohibited List it sits in class S9, not the anabolic steroid class S1. The distinction is not cosmetic. S1 substances are prohibited at all times. S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes.

Which means: a therapeutic glucocorticoid injection into the knee, administered out of competition, is entirely legal. It becomes a violation at the moment residues are present in an in-competition sample. The testing window for a road race opens at 23:59 the day before the race. A depot injection given three or four days out will be caught, even if it was given as treatment.

The defence in this case was never that the drug was not taken. The defence was when it was taken, by which route, by whom, and why. That defence is built out of documents alone.

She produced documents. The documents were forged. That is the centre of the case. The drug cost her two years. The paper cost her four more.

Two plus four: the arithmetic of the decision

Read the numbers. Two years for the presence violation is close to the standard outcome where the substance is specified and intent is not proven. Four years for tampering is the Code's standard sanction, not an exceptional escalation.

Two things follow. First, the panel granted no no-significant-fault reduction. Had it accepted that the athlete's fault was negligible, the presence sanction would have shrunk. It did not shrink. Second, the two charges were kept separate — legally correct, brutal in effect. Forged documents are themselves circumstantial evidence of an intent to conceal. Yet they did not aggravate the presence sanction; they added four years on their own.

There is a paradox worth noting. The tampering sanction is transparent; the presence sanction remains opaque, because we do not know how the panel weighed the knee-injury claim. Without the reasoned decision we can see the outcome but not the reasoning.

Backdating to 10 September is not a discount. Time served under provisional suspension counts against the ban. The athlete gains nothing in real terms. It is procedural accounting, not mercy.

Three document failures

This is the part I find most troubling and least quoted.

Failure one: the clinic printed on the prescription does not exist. Not in a register, not at an address.

Failure two: the signatory holds no medical registration. He is a family member.

Failure three: asked where the pad came from, the answer was a former workplace's clinic. That clinic disowns the claim.

Three independent verification checks. All three failed. Any one failure might have been survivable. All three is a pattern, and the AIU read it as one.

What stands out is that none of these three errors reads as naivety. Naivety happens once. Not three times.

Now the redaction audit. The statement names only the family member. It does not say whether the agent was investigated. It does not say whether the training group's medical staff were questioned. It does not say whether the same pad was used in anyone else's file.

That is the real redaction — not a struck-out name, but an unaddressed party. A 32-year-old elite distance runner does not manufacture paper alone. Someone advises, someone accepts, someone carries it forward. The statement is silent on that chain.

The gap file: what was not written is also a document

I am not alleging concealment. I am saying absence should be logged as absence.

No mark is given for the Chinese half marathon. The direct consequence is that no performance judgment is possible. No splits, no field quality, no season's best. We know only that she won — which implies a label-tier elite field with in-competition testing. That is all. Anyone who tells you what her form was is inventing it.

The disqualification scope is not given. This is the largest technical hole. Standard AIU practice is automatic annulment of the competition where the sample was collected. Which puts the March win, its prize money and any ranking points accrued after that date in question. The statement does not say so. I log this as inference, not fact.

There is no Ethiopian federation statement. That silence is not trivial. In a country whose soft power is distance running, not one national line on a six-year ban for a Tokyo Marathon winner is itself a document.

Why Tokyo 2026 survives

This is where most people err. A ban does not erase a career; it stamps a date on it. The violation is anchored to the March race. Absent a finding of earlier use, results before that date are not automatically annulled.

The 2026 Tokyo title and three Major second places remain on the record. What changes is not the record but its price.

Which is where the sport's economy and its ethics take different roads. Distance-running sponsorship is already thin. A former Major winner serving six years is of no use to a brand. The record book keeps her; the market does not.

The quota ledger: China's label circuit and the appearance fee

In Indian athletics the real wage is a Railways or police job, not prize money. In the East African marathon economy the real wage is the appearance fee, and for a decade its largest market has been China.

Between Majors, a 2:18–2:20 athlete's model is a handful of Chinese label races: low race count, low risk, decent fee. That was Aga's pattern after 2026 — selective Major racing plus Asian label appearances.

That same circuit is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races. The collision is not coincidental. Where money is dense and fields are deep, testing will be dense too.

The other half of that collision is medical. For an athlete living on appearance fees, a sore knee is the most expensive object she owns, because pain means a missed race and a missed fee. A glucocorticoid injection suppresses that pain more cheaply than anything else. And where the entourage has no formal medical structure — no registered team physician, no therapeutic use exemption file — the next step is manufacturing paper.

Forgery does not come from the drug. It comes from a place where there is no official route to treatment.

The age ladder: thirty-two to thirty-eight

Aga is 32. The ban runs six years from 10 September. A return lands near 38.

Look at Ethiopian women's marathon depth: a sub-2:16 cohort, the world record holder, multiple sub-2:14 performers. In that depth, a 38-year-old 2:18–2:20 athlete with a doping record is not in the selection conversation at all.

No dramatic forecast is needed. Only arithmetic. Six years at 32 is functionally a lifetime ban. And the thing that imposed it was not the drug. It was the paper.

One detail nags. In anabolic steroid cases the logic of sanction is clean: unfair advantage. In glucocorticoid cases that logic weakens, because the performance benefit for endurance is unproven. Yet six years lands — because the sanction is about process, not performance.

The hearing, the language, and that interview

The four-year tampering charge did not come from a document alone. It came from an interview — from statements made under questioning.

I am not claiming a translation failure. I have no evidence for that, and asserting it without evidence would betray the method. I am saying the reasoned decision should record which language the interview was conducted in, who interpreted, whether the question set was shared in advance, and whether the statement was transcribed and signed.

These are not technicalities. In East African road-running cases these details decide whether four years stands or falls. The day those documents are public, the argument restarts.

Prize money, ranking points, and the part the statement left out

Standard AIU practice annuls the competition where the sample was collected. If that applied here, the March win goes, the prize money is clawed back, and ranking points after that date are forfeited.

The statement does not say so. That silence can be read two ways: not yet settled, to appear in the reasoned decision; or treated as automatic and therefore not restated. Either reading requires a document we do not have.

I will put it plainly: this is inference, not fact. The difference is whether inference is labelled as such.

Those who say the ban is too long, and those who say it is too short

Both arguments will arrive. One side will call six years for a glucocorticoid disproportionate. The other will call the AIU rigorous and say rigour is required.

Both make the same mistake: they put the drug at the centre. The drug is not at the centre. The paper is. Had the knee treatment been documented properly — registered physician, real clinic, correct date, correct route — the case would not have reached this point. At worst there would have been a presence charge, and even there a no-significant-fault argument.

This case is not evidence that the rules are harsh. It is evidence that a 32-year-old world-class runner had no official route to treatment — or did not know of one.

That is the least-written point. By calling it a steroid, the media simplified the story. Simplification is not wrong, but it carries a cost: you start comparing this substance with substances it is not comparable to, and then the sanction looks incoherent.

The contrarian angle: what the critics skip

Three things stayed out of the debate.

First, the panel kept the two violations separate, which is legally correct. One consequence is that the forged paper did not aggravate the presence sanction — it added four years on its own. The real penalty was imposed by process, not pharmacology. Anyone arguing that the rules punish the drug has not read the arithmetic.

Second, the gaps in the statement are easy to read as conspiracy. No race name, no mark, no year, no scope. Mostly this is filing convention, not concealment. A press release is a press release. Asking it to do the reasoned decision's job is posting a letter to the wrong address. The right question is when the reasoned decision will be published.

Third, and most important: this case is not alone. A cluster is forming in East African road running where the first violation is the substance and the larger one is the explanation — a forged prescription, an altered document, a misleading statement. The enforcement frontier has shifted from detection to document verification. The AIU is no longer reading blood; it is reading paper.

And if the AIU is reading paper, the next question is how many athletes in the same training camps are carrying prescriptions from clinics that do not exist — and how we would ever know.

That question is not aimed at one athlete. It is aimed at a system where medical support is informal, the TUE process is distant, and manufacturing a document is cheaper than getting treatment.

Takeaway: three documents to watch

First, the reasoned decision. Look for the interview record, the language and interpretation note, and how the panel weighed the knee-injury claim. If all three are missing, there is appeal ground.

Second, the appeal window. A reasoned decision typically opens roughly 21 days. A document-based forgery finding is hard to overturn, so the odds are low. But the window is open, and its closing is a date worth logging.

Third, the Ethiopian federation's silence. If it breaks, we learn whether national-level accountability exists. If it does not, that silence belongs in the file too.

Aga won Tokyo in 2026. That win stays in the record, because a ban attaches to a date, not to a career. What does not stay is the trust an athlete places in her entourage's paperwork — and in this case that trust broke first, before the drug.

I did not write this to defend an athlete or to praise an institution. I wrote it because a six-year ban adds up to two plus four, and until we call that sum by its right name, we will repeat the same error in the next case.

The question was never which race she won. It was who signed the prescription, and who wrote down the clinic's address.